{"id":2866,"date":"2026-08-21T21:03:17","date_gmt":"2026-08-21T20:03:17","guid":{"rendered":"https:\/\/seamlessbio.de\/?p=2866"},"modified":"2026-08-21T21:03:19","modified_gmt":"2026-08-21T20:03:19","slug":"disease-state-serum-biomarker-research-guide","status":"publish","type":"post","link":"https:\/\/seamlessbio.de\/de\/disease-state-serum-biomarker-research-guide\/","title":{"rendered":"Disease State Serum"},"content":{"rendered":"

<\/p>\n

August 2026 \u00b7 6 min read<\/em><\/p>\n

Standard human AB serum comes from healthy, screened-negative donors. For many research and diagnostic applications, that is exactly what you need. But for IVD assay development, biomarker validation, and cross-reactivity testing, you need serum that contains the actual analyte or pathological condition you are measuring \u2014 disease state serum.<\/p>\n

What is disease state serum?<\/h2>\n

Disease state serum is human serum collected from donors with a defined, confirmed medical condition. Unlike standard serum \u2014 which is screened to exclude infectious agents and pathological markers \u2014 disease state serum is specifically collected from donors who test positive for a target analyte or carry a defined condition. It is the positive control material and challenge matrix for assay development.<\/p>\n

Disease state serum is not a research tool for studying the disease itself \u2014 it is a quality control and assay validation reagent<\/strong> for diagnostic test developers, immunoassay manufacturers, and biomarker researchers who need real-world positive samples.<\/p>\n

Key disease state serum categories<\/h2>\n

Infectious disease markers \u2014 for IVD assay development<\/h3>\n\n\n\n\n\n\n\n\n
Condition<\/th>\nAnwendung<\/th>\nKey notes<\/th>\n<\/tr>\n
HIV-1\/2 positive<\/td>\nAnti-HIV antibody assay development, NAT validation<\/td>\nAb-positive; RNA-positive (viremic) available separately<\/td>\n<\/tr>\n
HBsAg positive (HBV)<\/td>\nHBsAg immunoassay development, surface antigen quantification<\/td>\nVarious genotypes available; HBeAg status specified<\/td>\n<\/tr>\n
Anti-HCV positive<\/td>\nHCV antibody assay development, confirmatory testing<\/td>\nSeroconversion panels available for window period testing<\/td>\n<\/tr>\n
HCV RNA positive<\/td>\nNAT assay development, viral load quantification<\/td>\nGenotype-specific panels available<\/td>\n<\/tr>\n
Syphilis (T. pallidum) positive<\/td>\nTreponemal antibody assay development<\/td>\nRPR\/VDRL titres specified<\/td>\n<\/tr>\n
HTLV-I\/II positive<\/td>\nBlood bank screening assay development<\/td>\nRare \u2014 request availability<\/td>\n<\/tr>\n<\/table>\n

Autoimmune and inflammatory conditions<\/h3>\n\n\n\n\n\n\n\n
Condition<\/th>\nAnwendung<\/th>\n<\/tr>\n
Rheumatoid factor (RF) positive<\/td>\nInterference testing in immunoassays \u2014 RF is a major interferent in many sandwich ELISAs<\/td>\n<\/tr>\n
ANA positive (various patterns)<\/td>\nAnti-nuclear antibody assay development, autoimmune panel validation<\/td>\n<\/tr>\n
Anti-dsDNA positive<\/td>\nSLE biomarker assay development<\/td>\n<\/tr>\n
Anti-CCP positive<\/td>\nRheumatoid arthritis assay development<\/td>\n<\/tr>\n
High-sensitivity CRP elevated<\/td>\nhsCRP assay calibration and linearity verification<\/td>\n<\/tr>\n<\/table>\n

Metabolic and hormonal conditions<\/h3>\n\n\n\n\n\n\n\n\n
Condition \/ Marker<\/th>\nAnwendung<\/th>\n<\/tr>\n
25-OH Vitamin D deficient (<10 ng\/mL)<\/td>\nVitamin D immunoassay calibration \u2014 low-end linearity<\/td>\n<\/tr>\n
25-OH Vitamin D replete (>30 ng\/mL)<\/td>\nNormal range calibrator base matrix<\/td>\n<\/tr>\n
Hyperlipidemic (elevated triglycerides)<\/td>\nLipemia interference testing (CLSI EP7)<\/td>\n<\/tr>\n
Icteric (elevated bilirubin)<\/td>\nIcterus interference testing<\/td>\n<\/tr>\n
Haemolytic (elevated free haemoglobin)<\/td>\nHaemolysis interference testing<\/td>\n<\/tr>\n
Thyroid disorders (hypo\/hyperthyroid)<\/td>\nTSH, T3, T4 assay development<\/td>\n<\/tr>\n<\/table>\n

How disease state serum is used in IVD development<\/h2>\n

1. Cross-reactivity testing<\/h3>\n

Regulatory submissions for IVD devices (EU IVDR 2017\/746, FDA 510(k)) require demonstration that the assay does not cross-react with potentially interfering conditions. For an HIV antibody test, you must demonstrate no false positives in serum from donors with rheumatoid factor, ANA, HBV, HCV, malaria, and other conditions likely to be present in the tested population. Disease state serum panels provide the challenge samples for this validation.<\/p>\n

2. Assay sensitivity at the clinical decision limit<\/h3>\n

The clinical sensitivity of a diagnostic assay is measured by its ability to detect the analyte at or near the clinical decision threshold \u2014 the concentration above which a patient tests positive. Disease state serum with confirmed low-positive analyte concentrations (near the cutoff) tests the assay’s lower limit of detection under real-world matrix conditions.<\/p>\n

3. Interference testing (CLSI EP7)<\/h3>\n

Lipemic, icteric, and haemolytic serum samples are standard challenge materials for the CLSI EP7 interference protocol \u2014 required for most IVD submissions. SeamlessBio supplies pooled lipemic (triglycerides >1,000 mg\/dL), icteric (bilirubin >20 mg\/dL), and haemolytic (haemoglobin >500 mg\/dL) human serum for this application.<\/p>\n

4. Seroconversion panels for window period characterisation<\/h3>\n

HIV and HCV seroconversion panels \u2014 sequential samples from donors collected before, during, and after seroconversion \u2014 allow characterisation of how early an assay can detect infection. These are among the most valuable and difficult-to-source materials in IVD development.<\/p>\n

Regulatory and ethical considerations<\/h2>\n

Disease state serum is collected under informed consent from donors who are aware of their diagnosis and agree to use of their samples for research and diagnostic development. All SeamlessBio disease state serum is supplied with:<\/p>\n